Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-08-29 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-08-29 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is an announcement from Innate Pharma dated August 29, 2023. The primary content details the company's participation in upcoming investor conferences and, crucially, announces a conference call scheduled for September 14, 2023, to present its 'résultats financiers et l'avancée de son portefeuille au premier semestre 2023' (financial results and portfolio progress for the first half of 2023). This announcement is not the full financial report itself (which would be an IR or 10-K), nor is it the detailed management discussion of those results (MDA). It is an announcement *about* the upcoming release of results and the associated call. This fits the definition of an Earnings Release (ER) which is the 'Initial announcement of quarterly/periodical financial results (key highlights only)' or, more accurately in this context where the results are being presented via a call, it is an announcement related to the earnings event. However, looking closely at the definitions, the document is primarily an announcement detailing *when* the results presentation/call will happen and listing investor conferences. It is not the actual press release containing the key financial highlights (which is typically the ER). Since it is announcing the date and details for the presentation of H1 2023 results, it is most closely related to the Earnings Release process. Given the structure, which focuses on scheduling the results call, it is a precursor to the full ER or a specific announcement related to the earnings event. If the document contained the actual key financial figures (revenue, net income, EPS), it would be ER. Since it only announces the *event* where the results will be discussed, it functions as a notification about the upcoming earnings event. In many databases, this type of announcement is classified as an Earnings Release (ER) or sometimes a Report Publication Announcement (RPA) if it were only announcing the publication of a document. Since it explicitly mentions the 'Résultats financiers' call, ER is the most appropriate fit among the financial reporting categories, as it pertains directly to the earnings disclosure schedule. Considering the options, ER (Earnings Release) is the best fit because the core purpose is to schedule the presentation of the H1 2023 financial results.
2023-08-29 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release dated August 29, 2023, announcing the company's participation in upcoming investor conferences and scheduling a conference call for a 'First Half 2023 Business Update' on September 14, 2023. This announcement is not the full financial report (10-K or IR), nor is it the initial earnings release (ER) which typically contains the key figures. Instead, it is an announcement about future events, including participation in investor conferences and a call to discuss business progress. This fits best under the category of an Investor Presentation (IP) if it were the presentation itself, or more accurately, an announcement regarding investor relations activities. Since the document primarily details conference participation and the scheduling of a business update call, it relates closely to investor communications. However, the core purpose is to announce participation in external events and schedule a call to discuss business progress, which often precedes or accompanies an Interim Report (IR) or Earnings Release (ER). Given the specific mention of a 'First Half 2023 Business Update' conference call, this is an announcement related to investor engagement and future reporting/discussion. The closest fit among the provided options for an announcement detailing participation in investor conferences and scheduling a call to discuss business updates is 'Investor Presentation' (IP) as it is a form of investor communication, or potentially 'Report Publication Announcement' (RPA) if it were announcing the release of the H1 report itself. Since it is announcing participation in multiple conferences and a specific call for an update, it functions as a general investor relations update. Given the options, 'Investor Presentation' (IP) is often used broadly for investor-facing communications about strategy and updates, even if it's just an announcement of participation. However, if we strictly follow the definitions, this is an announcement about future events and participation, not the presentation material itself. The most fitting category for an announcement detailing participation in investor conferences and scheduling a call to discuss business progress is often captured by general investor communications. Since it is not the actual financial report (IR) or the initial earnings highlights (ER), and it is not announcing the publication of a report (RPA), 'Investor Presentation' (IP) is the best fit as it relates to investor-facing events and updates, even if the presentation material isn't attached here. Alternatively, it could be seen as a general Regulatory Filing (RNS) if no other category fits well. Given the focus on conference participation and a business update call, IP is chosen as the most relevant investor-focused category.
2023-08-29 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-08-10 English
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release dated August 10, 2023, announcing that members of the senior management team are scheduled to participate in an upcoming investor conference ('H.C. Wainwright Immune Cell Engager Virtual Conference'). This type of announcement, which informs investors about management's schedule for engaging with the market outside of formal earnings or regulatory filings, is best classified as an Investor Presentation (IP) or related communication, although it is not the presentation itself. However, given the options, this announcement is primarily focused on investor relations activities and scheduling participation in an investor event. It is not a formal financial report (10-K, IR, ER), a management change (MANG), or a dividend notice (DIV). Since it is an announcement about future investor engagement, it aligns most closely with the general category of Investor Presentation (IP) materials, even though it is an announcement *about* participation rather than the presentation itself. Given the short length and the nature of the content (announcing participation in a conference), it could also be considered a Regulatory Filing (RNS) if 'IP' is strictly reserved for the actual presentation deck. However, because the core subject is investor engagement/conference participation, 'IP' is the most contextually relevant choice among the specific options provided, as it relates directly to investor outreach.
2023-08-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated August 10, 2023, announcing the company's management team's participation in an upcoming investor conference ('H.C. Wainwright Immune Cell Engager Virtual Conference' on August 17, 2023). It provides company background, contact information, and standard forward-looking statements. This type of announcement, which informs investors about management's schedule for engaging with the investment community (like attending conferences), is typically classified as Investor Presentation (IP) if it were the presentation itself, or more generally as a communication aimed at investors regarding future engagement or strategy updates. Since it is an announcement about *attending* an event rather than the event material itself, and it is not a formal regulatory filing like 10-K or ER, it fits best under Investor Presentation (IP) as it is a direct communication to investors about future activities, or potentially Regulatory Filings (RNS) as a general announcement. Given the context of biotech companies frequently announcing conference participation to keep investors informed about visibility and pipeline discussions, 'IP' (Investor Presentation) is often used for materials related to investor outreach, but since this is purely an announcement of attendance, 'RNS' (Regulatory Filings/General Announcement) is a safer fallback if 'IP' is reserved for the actual presentation deck. However, looking at the definitions, 'IP' is for 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document is an announcement *about* investor engagement. Since it is a specific, non-standard announcement that doesn't fit ER, CT, or DIRS, and it's not announcing the release of a major report (RPA), it is best categorized as a general regulatory/investor communication. Given the options, and recognizing this is a standard corporate communication to the market about investor relations activities, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate general category for non-core financial/legal announcements.
2023-08-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.